Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference

MT Newswires Live12-03

Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.

In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.

Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.

Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588706497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 06:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588706497","market":"sg","top_or_hot":-1,"title":"Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference","media":"MT Newswires Live","content":"<html><body><p> Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.</p><p>In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.</p><p>Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.</p><p>Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-03 06:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.</p><p>In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.</p><p>Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.</p><p>Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588706497","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588706497","pubTimestamp":1764716292,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biogen  and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BIIB":"渤健公司","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"Biogen和卫材在2025年阿尔茨海默病临床试验会议上展示新的LEQEMBI生物标志物数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588706497","isCrawlerRequest":true}